This meta-analysis systematically evaluated the outcome of pulmonary vein isolation (PVI) with and without focal impulse and rotor modulation (FIRM) ablation in patients with atrial fibrillation.
Circ Arrhythm Electrophysiol. 2018;11:e005789. DOI: 10.1161/CIRCEP.117. 005789 March 2018 2 A trial fibrillation (AF) is a complex disease with limited understanding of the underlying mechanism responsible for the origin and perpetuation of the arrhythmia and transformation of a primarily pulmonary vein (PV)-centric paroxysmal AF in the beginning, to a predominantly non-PV source-driven arrhythmia of a more permanent kind over time. Catheter ablation has become a widely used strategy to treat patients with all types of AF. However, the ablation efficacy deteriorates in time with the degree of attrition being dependent on the severity of AF. 1 Thus, the search is on, to find adjunctive strategies that can fortify the durability of ablation success in AF patients, more so in the nonparoxysmal AF population.
One of the many newly emerging approaches gaining popularity among the electrophysiologists in the past 5 years is the focal impulse and rotor modulation (FIRM)-guided ablation that offers the tool for real-time mapping of both atria during AF. 2 Electrograms recorded by a basket catheter are analyzed by proprietary software to identify focal and recurring electric activity in a circular pattern called rotors, which are thought to be responsible for perpetuation of AF and thus targeted in the FIRM ablation. 2 If the rotors/focal sources are mechanisms that sustain AF, then it stands to reason that the ablation of these rotors should be associated with improved clinical outcomes. 3 In fact, series of single-center trials and registries have reported robust success rate of the FIRM ablation combined with the standard PV isolation (PVI) approach. [3] [4] [5] [6] [7] [8] However, other independent studies have failed to reproduce these findings with the FIRM+PVI procedure. [9] [10] [11] [12] [13] [14] Thus, it is still unclear if FIRM+PVI ablation has a definitive advantage over conventional PVI procedure in accomplishing long-term arrhythmia-free survival in AF patients. The significance of this information cannot be overemphasized given the fact that an additional FIRM ablation procedure requires longer procedure time and sizeable extra cost for the patients who are already burdened with the expenses and consequences of multiple potential ablation procedures to cure AF. However, there is no published study that has directly compared the 2 approaches with a randomized study design except the OASIS trial (Outcome of Different Ablation Strategies in Persistent and Long-Standing Persistent Atrial Fibrillation) that was retracted post-publication because of randomization errors. 15 Therefore, we systematically reviewed the medical literature to evaluate the long-term success rate of
WHAT IS KNOWN?
• In patients with nonparoxysmal atrial fibrillation, pulmonary vein isolation (PVI) alone is not sufficient to achieve durable arrhythmia-free survival, necessitating the search for adjunctive ablation strategies. • In the past 5 years, focal impulse and rotor modulation (FIRM)-guided ablation offering the tool for real-time mapping of both atria to identify rotors that are thought to be responsible for maintenance of atrial fibrillation has shown promising results by select studies.
• However, other independent trials have failed to demonstrate any advantage of rotor ablation when it is combined with PVI, in terms of longterm arrhythmia-free survival, although it substantially prolongs the procedure duration and is associated with increased cost. • There are no randomized trials published to date that directly compare the 2 ablation strategies, namely rotor ablation+PVI versus PVI alone.
WHAT THE STUDY ADDS?
• This is a pooled analysis of all relevant published studies with a minimum follow-up period of 1 year to evaluate the long-term outcome of PVI with and without rotor ablation in atrial fibrillation patients.
• Our meta-analysis, the first of its kind to contrast PVI versus PVI+FIRM ablation, demonstrated no therapeutic benefit of additional focal impulse and rotor modulation approach over PVI alone; long-term arrhythmia-free survival was comparable between the 2 groups, whereas the procedure duration was substantially longer with the addition of focal impulse and rotor modulation-guided ablation. FIRM+PVI procedure (reported mostly as single-arm studies) and compared the efficacy with that of the conventional PVI (performed as part of randomized trials) in AF patients.
METHODS
As this is a meta-analysis of published studies, the data are already publicly available for the researchers. 
Study Selection
Studies were selected by 2 independent reviewers. Citations initially selected by systematic search were first retrieved as a title and abstract and preliminarily screened. Studies that met the following criteria were retained for analyses: (1) studies published in past 3 years for the PVI-only trial; (2) report single-procedure success rate off-antiarrhythmic drugs (AAD); (3) minimum follow-up period of 1 year; (4) must be a randomized control trial (RCT) randomly allocating patients to the PVI-only arm; (5) at least part of the study population is nonparoxysmal AF; and (6) the study must be published in a peer-reviewed English scientific journal. Studies with exclusively paroxysmal AF population were not included. One hundred fifty-seven articles were selected for detail checking from the initially screened 2386 publications. Of the 157, 120 articles were excluded for the following reasons: 68 review articles, 34 studies where ablation success was not reported or were published >5 years ago or were not RCTs for the PVI approach, and 18 editorials or comments. This yielded 37 articles of which 16 were excluded for not being independent trials (ie, original studies promoted by academic or nonprofit organizations; not company sponsored), and 6 were removed either because the study population was entirely paroxysmal AF or the follow-up period was <12 months; thus, 15 studies (10 FIRM+PVI and 5 PVI only [RCT]) were eligible for inclusion in this study. For each of the studies, full text of the original article was downloaded ( Figure 1 ).
Data Extraction and Quality Assessment
Disagreements between reviewers were resolved by a third blinded reviewer. Study quality was evaluated according to the established methods of the Cochrane Collaboration. 16 Specifically, we separately estimated the risk of selection, performance, and detection bias.
Data Synthesis and Analysis
The prespecified primary outcome for this meta-analysis was long-term success rate (≥12-month follow-up). The off-AAD success rate was collected for the target population. The standard error and asymptotic variance were computed for the success rate. In the presence of significant variance in the study outcome, we performed appropriate sensitivity analyses to validate the pooled measurement. Meta-analysis assessing the primary end point was performed using DerSimonian and Laird random-effect model, and pooled ablation success estimates were obtained. In the random-effect model, studies were weighted with the inverse of their variance and the heterogeneity parameter or the between-studies variance. Standardized mean difference, Cohen's D was, computed to assess the difference in procedure time between the groups. Cohen's D was calculated as the difference between the means divided by the pooled SD. Cochran Q statistic, which represents the total variance, was used to measure the amount of between-study heterogeneity. The observed total variance was decomposed to isolate within-study variance and between-studies variance called τ 2 . When pooled estimates from fixed-and random-effect models were different, the relatively more conservative random-effect estimates were presented. I 2 statistic, which describes the percentage of variation across studies that is because of heterogeneity, is presented along with the pooled estimates. Effect size between groups was compared using Q test based within-study and between-study variance analysis. The Q represents the weighted sum of squared mean for studies FIRM+PVI and PVI about the combined effect of all studies. This analysis tests the null hypothesis that the effect sizes are the same for all groups.
Publication bias was assessed using the asymmetry linear regression of Egger test and visually, as funnel plot of precision. A test of the null hypothesis that the regression slope equals zero provides a test of publication bias. The study was performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Statistical level of significance was defined at a 2-tailed P <0.05. Heterogeneity and publication bias were considered statistically significant at a 2-tailed P value of <0.10. Analyses were performed using SAS 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
This meta-analysis compared the single-procedure off-AAD success rate at ≥1-year follow-up in patients undergoing FIRM+PVI versus just PVI in prospective trials that enrolled a mixture of patients with all types or exclusively nonparoxysmal AF. A total of 15 studies, 10 studies with FIRM+PVI 
Characteristics of the Studies
The demographic and clinical characteristics of the study population are presented in Tables 1 and 2 
Primary Outcome (Procedure Success)
After 15.9±5.5 (median 12) months follow-up, the off-AAD pooled success rate was 50% (95% confidence interval, 28%-72%) in PVI+FIRM and 58% (95% confidence interval, 46%-71%) in the PVI group (Figure 2) . Difference in success rate between the groups was compared using a Q test-based variance analysis. Q statistic for FIRM+PVI was 7.8 (df=9 and was 2.1 (df=4) for PVI studies. The between group variance was 1.57 (df=1), which did not show statistically significant difference in effect size (P=0.21). Thus, the overall pooled estimate did not indicate any clinically relevant or statistically sig- Difference between the groups was compared using a Q test-based variance analysis. No statistically significant benefit of the pooled effect size was observed in the FIRM+PVI group compared with PVI (50%; 95% confidence interval] CI, 28%-72% FIRM+PVI, and 58%; 95% CI, 46%-71% in PVI; P=0. 21 
Assessment of Bias
Estimation of publication bias was assessed for each cohort.
Results from Egger regression did not show any significant evidence of such bias (Egger ordinary least squares regression P=0.17 for FIRM+PVI and P=0.68 for PVI).
DISCUSSION
To the best of our knowledge, this is the first metaanalysis reporting a comparison between the FIRM+PVI ablation and the conventional PVI approach. Our main findings were the following: (1) the rate of off-AAD freedom from any atrial arrhythmia was comparable between the 2 approaches at ≥1-year follow-up, and (2) procedure duration was significantly longer in the FIRM+PVI group. In a recently published trial, Miller et al 7 reported the largest registry data on FIRM+PVI ablation as a singlearm study, and while discussing their limitations, they stated that their findings must be compared with those of PVI alone in a randomized trial. Given the fact that OASIS, the only randomized trial published to date, was retracted for methodological issues, 15 we examined the pooled success rate of all FIRM+PVI studies with at least 1-year follow-up and compared it with that of the conventional PVI where patients were randomly assigned to that procedure. That was the best that could be done to get a fair comparison between the 2 strategies (with at least 1 arm being part of an RCT) while awaiting the publication of other randomized trials that are under way.
Persistent AF is a disease of chronicity with progressive atrial fibrosis and evolving PV and extra-PV triggers. 26 Thus, PVI alone has a lower success rate in this population compared with the paroxysmal AF cohort. 27 To retain the rigorousness of this meta-analysis, we decided to include the RCTs that reported on success rate of conventional PVI in mostly or exclusively persistent AF population. However, in the comparator (FIRM+PVI) arm, all trials had paroxysmal AF patients included. Second, it is well known that multiple procedures yield higher success rate in all types of AF. In the current analysis, studies included in the PVI arm had patients undergoing their first ablation procedure, whereas in the FIRM+PVI arm, more than half of the patients had received earlier ablations. The pooled outcome data still remained comparable between the 2 strategies; adding rotor ablation to PVI (which was repeat procedure in more than half of the population) plus lines and ablation of clinically relevant atrial tachyarrhythmia in the FIRM+PVI group did not provide any added measurable benefit at the expense of additional procedure time and the extra cost of rotor mapping.
This observation has several plausible explanations. High variance in the success rate was noticed in 3 trials using FIRM+PVI ablation strategy that could have possibly impacted the pooled success rate. 9, 10, 20 The observed success rate at 18-month follow-up was 21% and 12% in the trials conducted by Buch et al 9 and Steinberg et al, 10 respectively. The authors provided several potential reasons that could be argued to have contributed to such inferior outcome, such as inadequate identification of the rotor sites because of poor contact by the basket catheter, temporal instability of the rotors, selection bias by including a population with 67% 9 and 72% 10 having previously failed ablation procedures and the learning curve effect. However, given the fact that the proprietary mapping algorithm identified rotors in every single patient and many of the procedures were conducted by experienced operators who had already participated in the initial rotor-mapping trials 10 and one being a developer of the system, 9 poor identification of the rotors and lack of skill were very unlikely reasons for this low success rate. 9 It is also really hard to prove that inclusion of majority with redo procedures was a contributing factor because Spitzer et al 8 had 100% patients with previously failed PVI, yet they observed 69.2% success rate of FIRM+PVI at 1-year follow-up. Last, the Johns Hopkins study observed a success rate of 38% at 1-year follow-up in an exclusively nonparoxysmal AF population with mean AF duration of 4.4 years and ≥50% with earlier failed ablations. 20 These population characteristics might explain their poor results. However, in this context, it is important to mention that it is still uncertain if the rotors are really responsible for AF maintenance or are a passive epiphenomenon of disorganized fibrillatory activation. 9, 11, 28 In the study conducted by Yamabe et al, 11 AF was terminated by PVI alone without additional radiofrequency lesions in patients with rotors. Other investigators did not detect any rotational activity at all. 20 In the study by Benharash et al 12 that evaluated the FIRM-mapping approach by analyzing quantitative characteristics of atrial electrograms used to identify rotors, ECG characteristics expected from rotors were not observed. Moreover, the electrograms did not differ quantitatively from the surrounding tissue. 12 Identification of stable rotating waves and focal sources of AF, as used in the FIRM approach, is based on the construction of electrogram phase maps and identification of phase singularity points and point sources of activation. 29 Random alignment of activations is known to often result in false-positive detection of phase singularity. 29 Hence, in the absence of any conclusive evidence as to why several independent trials failed to replicate the high suc- cess rate reported by others, it is prudent to speculate that the areas identified by the FIRM-mapping software were not related to the pathophysiological mechanisms underlying the arrhythmia. 9 In the FIRM+PVI studies, a sizeable proportion of cases had failed prior PVIs indicating the refractoriness of their arrhythmia. That could be another reason for having a mediocre pooled success rate of 50% after the hybrid procedure. However, earlier RCTs have shown comparable rate of freedom from atrial arrhythmias in nonparoxysmal AF patients who received repeat PVI. 30, 31 Drug-free 1-year multiple procedure success rate was 51.4% in the PVI-alone population in the CHASE-AF study (Catheter Ablation of Persistent Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation) and 54% in the RCT conducted by Estner et al. 30, 31 Moreover, in the AATAC trial (Ablation vs Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device), the success rate was 72% at 24 months after an average of 1.4±0.6 procedures (extended PVI) in patients with persistent AF and congestive heart failure. 32 Thus, it is unlikely that the refractoriness of the arrhythmia negated the benefits of rotor ablation in the population undergoing FIRM+PVI procedure. To provide a stringent comparison, we selected only those trials that had patients randomly assigned to the PVI procedure (conducted in the past 3 years) and were monitored for arrhythmia recurrence for at least a year. [21] [22] [23] [24] [25] All studies enrolled only nonparoxysmal AF patients except one that had 57% paroxysmal AF. PVI procedure and the arrhythmia-monitoring protocol were more or less similar between the 2 study groups (Tables 1  and 2 ). The pooled single-procedure off-AAD success rate was 58% with PVI, whereas it was 50% for the FIRM+PVI approach (P=0.21). Thus, after careful comparison between the 2 strategies, we failed to demonstrate any benefit of the additional rotor ablation in terms of long-term arrhythmia-free survival, in AF patients.
Last, the procedure time was significantly longer in the FIRM+PVI group. In the recently published study by Miller et al, 7 a group with extensive experience in this procedure, the mean procedure duration was nearly 6 hours and the duration of FIRM mapping and ablation was 1.5 hours. This observation raises few obvious questions; if the mean procedure duration was 6 hours in the hands of these skilled operators, how much longer would it be for the investigators with less experience in FIRM mapping and if the FIRM+PVI procedure does not provide higher long-term success compared with PVI only, why to expose the patients to such long procedures and extra cost of FIRM-guided ablation. Future RCTs will optimistically answer these questions. 
Limitations
We acknowledge certain weaknesses in the current meta-analysis: (1) the comparison groups came from different types of trials; whereas FIRM+PVI studies were consecutive series with inherent selection bias, all PVI trials were part of RCTs with their characteristic stringent methodological measures. However, by doing so, we provided the comparative findings closest to an RCT evaluating ablation outcome in patients randomly assigned to both arms. Also, no selection bias and significant heterogeneity were detected in our meta-analysis.
(2) Heterogeneity in the arrhythmia-monitoring method was another limitation; some studies used implantable devices, whereas others follow the standard quarterly follow-up with ECG, Holters, and event recorders. This could have resulted in differential assessment of recurrence rates. However, earlier trials have shown comparable detection rate by both methods plus false positives are more frequent with implantable recorders.
33,34

Conclusions
The findings from this meta-analysis demonstrated no therapeutic benefit of PVI+FIRM approach over PVI alone, even at the expense of a very long procedure time, which suggests the need to reevaluate the clinical use of FIRM ablation in AF.
